Hostname: page-component-78c5997874-s2hrs Total loading time: 0 Render date: 2024-11-01T06:10:49.829Z Has data issue: false hasContentIssue false
  • English
  • Français

Meet Our Board Members

Published online by Cambridge University Press:  12 February 2013

Humberto Nicolini
Humberto Nicolini*
Affiliation:
Chief of the Laboratory of Psychiatric Genetics at Psychiatric Services and the National Institute of Genomic Medicine in the Minister of Health Director, OCD Mexican Association and Carracci Medical Group in Mexico City
Get access Rights & Permissions [Opens in a new window]

Abstract

An abstract is not available for this content so a preview has been provided. Please use the Get access link above for information on how to access this content.
Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'
Type
Meet Our Board Members
Information
CNS Spectrums , Volume 18 , Issue 1 , February 2013 , pp. 55 - 57
Copyright
Copyright © Cambridge University Press 2013

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1.Fiestas, F, Gallo, C, Poletti, G, etal. What challenges does mental and neurological health research face in Latin American countries? Rev Bras Psiquiatr. 2008; 30(4): 328–336.CrossRefGoogle ScholarPubMed
2.Mari, JJ, Patel, V, Kieling, C, etal. The 5/95 gap in the indexation of psychiatric journals of low- and middle-income countries. Acta Psychiatr Scand. 2010; 121(2): 152–156.CrossRefGoogle ScholarPubMed
3.Minaya, O, Fresán, A, Cortes-Lopez, JL, Nanni, R, Ugalde, O. The Benzodiazepine Dependence Questionnaire (BDEPQ): validity and reliability in Mexican psychiatric patients. Addict Behav. 2011; 36(8): 874–877.CrossRefGoogle ScholarPubMed
4.Apiquian, R, Elena Ulloa, R, Herrera-Estrella, M, etal. Validity of the Spanish version of the Personal and Social Performance scale in schizophrenia. Schizophr Res. 2009; 112(1–3): 181–186.CrossRefGoogle ScholarPubMed
5.Prado Hda, S, do Rosário, MC, Shavitt, RG, Miguel, EC. Sensory phenomena, “just-right” and “not just-right” experiences in OCD patients: looking for a consensus. CNS Spectr. 2007; 12(2): 95–96.Google ScholarPubMed
6.Fresán, A, De la Fuente-Sandoval, C, Loyzaga, C, etal. A forced five-dimensional factor analysis and concurrent validity of the Positive and Negative Syndrome Scale in Mexican schizophrenic patients. Schizophr Res. 2005; 72(2–3): 123–129.CrossRefGoogle ScholarPubMed
7.Robles-Garcia, R, Páez Agraz, F, Ascensio Guirado, M, Mercado Salcedo, E, Hernández Muñoz, L. Evaluation of suicide risk in children: psychometric properties of the Spanish version of the Risk of Suicide Questionnaire (RSQ). Actas Esp Psiquiatr. 2005; 33(5): 292–297.Google ScholarPubMed
8.Robles-García, R, Páez Agraz, F, Zúñiga Partida, O, Rizo Méndez, A, Hernández Villanueva, E. Beliefs About Voices Questionnaire (BAVQ): Spanish translation and psychometric properties. Actas Esp Psiquiatr. 2004; 32(6): 358–362.Google ScholarPubMed
9.Robles García, R, Salazar Alvarado, V, Páez Agraz, F, Ramírez Barreto, F. Assessment of drug attitudes in patients with schizophrenia: psychometric properties of the DAI Spanish versión. Actas Esp Psiquiatr. 2004; 32(3): 138–142.Google ScholarPubMed
10.Rosario-Campos, MC, Miguel, EC, Quatrano, S, etal. The Dimensional Yale-Brown Obsessive-Compulsive Scale (DY-BOCS): an instrument for assessing obsessive-compulsive symptom dimensions. Mol Psychiatry. 2006; 11(5): 495–504.CrossRefGoogle ScholarPubMed
11.Ulloa, RE, de la Peña, F, Higuera, F, etal. Validity and reliability of the Spanish version of Yale-Brown Obsessive-Compulsive Rating Scale for children and adolescents. Actas Esp Psiquiatr. 2004; 4(32): 216–221.Google Scholar
12.Apiquian, R, Fresan, A, Ulloa, RE, etal. Amoxapine as an atypical antipsychotic: a comparative study vs risperidone. Neuropsychopharmacology. 2005; 30(12): 2236–2244.CrossRefGoogle ScholarPubMed
13.Illescas-Rico, R, Páez-Agraz, F, Arreola-Chávez, F, etal. Effectiveness and security of venlafaxine XR in the treatment of major depression. Rev Med Inst Mex Seguro Soc. 2005; 43(6): 473–478.Google ScholarPubMed
14.Nicolini, H, Bakish, D, Duenas, H, etal. Improvement of psychic and somatic symptoms in adult patients with generalized anxiety disorder: examination from a duloxetine, venlafaxine extended-release and placebo-controlled trial. Psychol Med. 2009; 39(2): 267–276.CrossRefGoogle ScholarPubMed
15.De la Fuente, JR, Berlanga, C, León-Andrade, C. Mania induced by tricyclic-MAOI combination therapy in bipolar treatment-resistant disorder: case reports. J Clin Psychiatry. 1986; 47(1): 40–41.Google ScholarPubMed
16.Salín-Pascual, RJ, Rosas, M, Jimenez-Genchi, A, Rivera-Meza, BL, Delgado-Parra, V. Antidepressant effect of transdermal nicotine patches in nonsmoking patients with major depression. J Clin Psychiatry. 1996; 57(9): 387–389.Google ScholarPubMed
17.Apiquian, R, Fresán, A, de la Fuente-Sandoval, C, Ulloa, RE, Nicolini, H. Survey on schizophrenia treatment in Mexico: perception and antipsychotic prescription patterns. BMC Psychiatry. 2004; 274: 12.CrossRefGoogle Scholar
18.Estrada-Camarena, E, Fernández-Guasti, A, López-Rubalcava, C. Antidepressant-like effect of different estrogenic compounds in the forced swimming test. Neuropsychopharmacology. 2003; 28(5): 830–838.CrossRefGoogle ScholarPubMed
19.Apiquian, R, Córdoba, R, Louzã, M. Clinical outcomes of long-acting injectable risperidone in patients with schizophrenia: six-month follow-up from the Electronic Schizophrenia Treatment Adherence Registry in Latin America. Neuropsychiatr Dis Treat. 2010; 22(7): 19–26.CrossRefGoogle Scholar
20.Ulloa, RE, Nicolini, H, Avila, M, Fernández-Guasti, A. Age onset subtypes of obsessive compulsive disorder: differences in clinical response to treatment with clomipramine. J Child Adolesc Psychopharmacol. 2007; 17(1): 85–96.Google ScholarPubMed
21.Salín-Pascual, RJ, Herrera-Estrella, M, Galicia-Polo, L, Rosas, M, Brunner, E. Low delta sleep predicted a good clinical response to olanzapine administration in schizophrenic patients. Rev Invest Clin. 2004; 56(3): 345–350.Google ScholarPubMed
22.Salin-Pascual, RJ, Herrera-Estrella, M, Galicia-Polo, L, Laurrabaquio, MR. Olanzapine acute administration in schizophrenic patients increases delta sleep and sleep efficiency. Biol Psychiatry. 1999; 46(1): 141–143.CrossRefGoogle ScholarPubMed
23.Salin-Pascual, RJ, Moro-Lopez, ML. Effects of venlafaxine in the sleep architecture of rats. Psychopharmacology (Berl). 1997; 129(3): 295–296.CrossRefGoogle ScholarPubMed
24.Mari, JJ, Patel, V, Kieling, C, Razzouk, D, Tyrer, P, Herrman, H. The 5/95 gap in the indexation of psychiatric journals of low- and middle-income countries. Acta Psychiatr Scand. 2010; 121(2): 152–156.CrossRefGoogle ScholarPubMed